This summary was created by AI, based on 1 opinions in the last 12 months.
Based on the reviews from different experts, it is evident that Seres Therapeutics (MCRB-Q) is poorly run and is experiencing substantial financial losses. This indicates a lack of effective management and financial stability, which could affect the company's long-term viability. Investors should approach this stock with caution and conduct thorough research before considering any investment.
Seres Therapeutics is a American stock, trading under the symbol MCRB-Q on the NASDAQ (MCRB). It is usually referred to as NASDAQ:MCRB or MCRB-Q
In the last year, 1 stock analyst published opinions about MCRB-Q. 0 analysts recommended to BUY the stock. 1 analyst recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Seres Therapeutics.
Seres Therapeutics was never recommended as a Top Pick on Stockchase. Read the latest stock experts ratings for Seres Therapeutics.
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
In the last year 1 stock analyst on Stockchase covered Seres Therapeutics. The stock is worth watching.
On 2024-05-02, Seres Therapeutics (MCRB-Q) stock closed at a price of $1.1.
Poorly run, and it's losing money hand over fist.